Chrysalis Biotherapeutics, Inc.

Galveston, TX

UEI
XW1VFGGRLDW3
CAGE
5DAY4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1700 The Strand, Galveston, TX 77550, USA
Website
chrysbio.com
Founded
2009
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 -$11,857,903

Contract awards

Award Agency Obligated Awarded
Demonstrate large animal efficacy, define protocols for the pivotal animal trial, and better understand the… 75A50119C00016 Office of the Assistant Secretary for Preparedness and Response $13,030,326
TP508: a novel nuclear countermeasure targeting endothelial cells and stem cellsto combat ARS and delayed multiple… HHSN272201700011C National Institute of Allergy and Infectious Diseases (NIH) $6,954,509
TP508 mitigates radiotherapy-induced tissue damage - period of performance 9/20/2013 - 9/19/2015 HHSN261201300076C National Cancer Institute (NIH) $1,499,884
Definitive Contract HHSN261201100035C National Cancer Institute (NIH) $199,757

Grant awards

Award Agency Obligated Awarded
Prevention of allergic rhinitis with topical immunomodulating antibodies R41AI093032 National Institutes of Health $300,000
TP508: a new drug for mitigating lethal effects of radiatin exposure R44AI086135 National Institute of Allergy and Infectious Diseases (NIH) $5,789,079
TP508:a new drug for mitigating lethal effects of radiation exposure R43AI086135 National Institutes of Health $297,326

Similar vendors

Vendor Location Primary NAICS
Primetime Life Sciences, LLC UEI UK3VUKCQM7N4 Germantown, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Pharmaceutical UEI Z2U4MHL9GAA8 New Albany, OH 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Antiviral Technologies, LLC UEI KCDDUKEQGMQ6 Dallas, TX 325412 Pharmaceutical Preparation Manufacturing
Epigenetix, Inc. UEI KVPSHD32BK67 Delray Beach, FL 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Molecular Diagnostic Services UEI PJ83K2PMLUV6 San Diego, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

SBA capabilities narrative

From the vendor's SBA profile

Therapeutic Drug Development

Quick answers

Is Chrysalis Biotherapeutics, Inc. registered in SAM.gov?

Yes. Chrysalis Biotherapeutics, Inc.'s SAM.gov registration is active through August 6, 2027.

What is Chrysalis Biotherapeutics, Inc.'s CAGE code?

Chrysalis Biotherapeutics, Inc.'s CAGE code is 5DAY4, and its Unique Entity ID (UEI) is XW1VFGGRLDW3.

What is Chrysalis Biotherapeutics, Inc.'s most recent federal award?

Chrysalis Biotherapeutics, Inc.'s most recent federal contract award is Demonstrate large animal efficacy, define protocols for the pivotal animal trial, and better understand the… (75A50119C00016), from Office of the Assistant Secretary for Preparedness and Response, on July 1, 2019.

On GovTribe

See Chrysalis Biotherapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe